| Literature DB >> 26029209 |
Karin de Punder1, Leo Pruimboom2.
Abstract
Chronic non-communicable diseases (NCDs) are the leading causes of work absence, disability, and mortality worldwide. Most of these diseases are associated with low-grade inflammation. Here, we hypothesize that stresses (defined as homeostatic disturbances) can induce low-grade inflammation by increasing the availability of water, sodium, and energy-rich substances to meet the increased metabolic demand induced by the stressor. One way of triggering low-grade inflammation is by increasing intestinal barrier permeability through activation of various components of the stress system. Although beneficial to meet the demands necessary during stress, increased intestinal barrier permeability also raises the possibility of the translocation of bacteria and their toxins across the intestinal lumen into the blood circulation. In combination with modern life-style factors, the increase in bacteria/bacterial toxin translocation arising from a more permeable intestinal wall causes a low-grade inflammatory state. We support this hypothesis with numerous studies finding associations with NCDs and markers of endotoxemia, suggesting that this process plays a pivotal and perhaps even a causal role in the development of low-grade inflammation and its related diseases.Entities:
Keywords: endotoxemia; endotoxin; inflammation; intestinal permeability; lipopolysaccharide; stress; tight junction
Year: 2015 PMID: 26029209 PMCID: PMC4432792 DOI: 10.3389/fimmu.2015.00223
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1MLC phosphorylation increases intestinal permeability. Activation of the SNS increases intestinal permeability by stimulating the activity of SGLT1 on epithelial cells. Activation of SGLT1 is paralleled by MLC phosphorylation by MLCK, inducing actomyosin contraction and reorganization of the tight junction. The resulting increase in paracellular permeability raises the possibility of translocation of bacteria and/or their toxins across the more permeable gut barrier. Pro-inflammatory cytokines produced by activated immune cells residing in the lamina propria further increase intestinal permeability by activating MLCK. JC, junctional complex.
Figure 2The complex neuroendocrine–immune interactions and their relation to gut barrier function. Stressors, including inflammatory mediators, activate the SNS and HPA-axis. Activation of the HPA-axis stimulates neurons in the paraventricular nucleus of the hypothalamus to secrete CRH and AVP that trigger the release of ACTH from the anterior pituitary, resulting in the secretion of corticosteroids from the adrenal cortex. CRH has been shown to affect intestinal permeability. SNS activation results in the release of catecholamines from the adrenal medulla. The intestinal wall is innervated by adrenergic sympathetic nerve fibers that upon stimulation increase water, sodium, and glucose absorption, paralleled by increased intestinal permeability. The resulting increase in translocation of endotoxin across the intestinal barrier can stimulate immune cells in the underlying lamina propria to secrete pro-inflammatory cytokines and prostaglandins like PGE2. Inflammatory mediators communicate with the brain by stimulating afferent sensory nerve fibers, by entering the brain via the circumventricular organs or by binding to cerebral blood vessel endothelium. Continuous stress-induced impairment of the intestinal barrier creates a vicious circle whereby inflammatory cytokines will persistently activate the SNS and HPA-axis resulting in barrier disruption, increased endotoxin translocation, and a pro-inflammatory state.
Associations found between markers of endotoxemia and disease.
| Reference | Disease | Marker(s) of endotoxemia | Effect |
|---|---|---|---|
| ( | Metabolic syndrome | Serum LPS | LPS levels correlated positively with symptoms of metabolic syndrome |
| ( | Obesity-related insulin resistance | Serum LBP | LBP levels increased |
| ( | Psoriasis/metabolic syndrome | Serum LBP | LBP levels only increased in psoriasis patients with metabolic syndrome |
| ( | Obesity | Plasma LBP | LBP levels increased |
| ( | NAFLD | Plasma LPS | LPS levels increased |
| ( | NAFLD | Serum LPS | LPS levels increased |
| ( | Obesity/NAFLD | Plasma LBP | LBP levels increased |
| ( | Liver disease | Plasma LPS | LPS levels increased |
| ( | Type 2 diabetes | Serum LPS | LPS levels increased |
| ( | Type 2 diabetes | Plasma LPS | LPS levels increased |
| ( | Type 2 diabetes | Serum LPS | LPS levels increased |
| ( | Diabetes | Serum LPS | LPS levels increased |
| ( | Type 2 diabetes, impaired glucose tolerance | Serum LPS | LPS levels increased |
| ( | Cardiovascular diseases | Serum LPS, serum IgA/IgG against oral bacteria | LPS levels increased, no differences in IgA/IgG levels |
| ( | Coronary artery disease | Plasma LBP | LBP levels increased |
| ( | Coronary artery disease | Serum LBP | LBP levels increased |
| ( | Arteriosclerosis | Serum LBP | LBP levels increased |
| ( | Arteriosclerosis | Plasma LBP | LBP levels increased |
| ( | Chronic heart failure (edematous) | Plasma LPS | LPS levels increased in edematous vs. non-edematous patients. No differences between all patients vs. controls |
| ( | Chronic heart disease (edematous) | Plasma LPS | LPS levels increased in edematous vs. non-edematous patients |
| ( | IBD | Serum LPS, LBP, sCD14 | LPS, LBP, sCD14 levels increased |
| ( | IBD | Plasma LPS, LBP, sCD15, endoCAbs | No differences in levels of LPS, sCD14, and endoCAbs. LBP levels increased |
| ( | IBD | Plasma LPS, endoCAbs | LPS and endoCAbs levels increased with disease severity |
| ( | Parkinson’s disease | Serum LBP, | LBP levels decreased, increased LPS infiltration in intestinal tissue |
| ( | Autism | Serum LPS, sCD14 | LPS levels increased, no differences in sCD14 levels |
| ( | Sporadic amyotrophic lateral sclerosis, Alzheimer’s disease | Plasma LPS | LPS levels increased |
| ( | Depression | Serum IgA/IgM against intestinal bacteria | IgA/IgM levels increased |
| ( | Chronic fatigue syndrome | Serum IgA/IgM against intestinal bacteria | IgA/IgM levels increased |
| ( | Alzheimer’s disease | Serum IgG against oral bacteria | IgG levels increased |